Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Chronic lymphocytic leukemia (CLL) exhibits variable clinical courses, necessitating prognostic models.
• Lack of consensus on follow-up and treatment strategies requires tools to identify high-risk patients early.

Purpose of the Study:

• To evaluate the applicability of the International Prognostic Score for Early-stage CLL (IPS-E) and the alternative IPS-E (AIPS-E) in a Middle Eastern cohort.
• To identify predictors of disease progression and treatment initiation in early-stage CLL.

Main Methods:

• Retrospective analysis of 212 Binet stage A CLL patients.
• Assessment of IPS-E and AIPS-E for risk stratification.
• Evaluation of demographic and clinical characteristics, including immunoglobulin heavy chain gene (IGHV) mutation status and chromosomal deletions (11q or 17p).

Main Results:

• Both IPS-E and AIPS-E identified a significant proportion of patients as high-risk for progression.
• Unmutated IGHV and elevated absolute lymphocyte count were significant predictors of earlier treatment.
• The prognostic scores demonstrated good discrimination for time to first treatment (c-statistics 0.74 for IPS-E, 0.69 for AIPS-E).

Conclusions:

• IPS-E and AIPS-E are valuable tools for identifying high-risk patients with early-stage CLL.
• These prognostic indices aid in risk stratification, guiding potential treatment initiation.